Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Intern Med ; 168(4): 351-6, 2008 Feb 25.
Article in English | MEDLINE | ID: mdl-18299488

ABSTRACT

BACKGROUND: The percentage of patients with community-acquired pneumonia (CAP) whose time to first antibiotic dose (TFAD) is less than 4 hours of presentation to the emergency department (ED) has been made a core quality measure, and public reporting has been instituted. We asked whether these time pressures might also have negative effects on the accuracy of diagnosis of pneumonia. METHODS: We performed a retrospective review of adult admissions for CAP for 2 periods: group 1, when the core quality measure was a TFAD of less than 8 hours; and group 2, when the TFAD was lowered to less than 4 hours. We examined the accuracy of diagnosis of CAP by ED physicians. RESULTS: A total of 548 patients diagnosed as having CAP were studied (255 in group 1 and 293 in group 2). At admission, group 2 patients were 39.0% less likely to meet predefined diagnostic criteria for CAP than were group 1 patients (odds ratio, 0.61; 95% confidence interval, 0.42-0.86) (P = .004). At discharge, there was agreement between the ED physician's diagnosis and the predefined criteria for CAP in 62.0% of group 1 and 53.9% of group 2 patients (P = .06) and between the ED physician's admitting diagnosis and that of the discharging physician in 74.5% of group 1 and 66.9% of group 2 patients (P = .05). The mean (SD) TFAD was similar in group 1 (167.0 [118.6] minutes) and group 2 (157.8 [96.3] minutes). CONCLUSION: Reduction in the required TFAD from 8 to 4 hours seems to reduce the accuracy by which ED physicians diagnose pneumonia, while failing to reduce the actual TFAD achieved for patients.


Subject(s)
Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Community-Acquired Infections/diagnosis , Community-Acquired Infections/drug therapy , Diagnostic Errors , Female , Humans , Male , Middle Aged , Retrospective Studies , Time Factors
2.
J Emerg Med ; 31(4): 395-401, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17046481

ABSTRACT

Quinine and quinidine have been cited as drugs that may cause significant morbidity and mortality in toddlers who ingest one or two pills. The use of both of these drugs has declined in the United States since the 1980s. A review of the literature and Poison Control data reveals that large quinine and quinidine ingestions, although rare in this country, may lead to severe toxicity and death related to cardiovascular and neurological effects in both children and adults. Although the majority of cases of quinine and quinidine toxicity in toddlers occur after ingestions of more than two pills, a single report each of severe toxicity after the equivalent of an ingestion of two pills or less by a toddler exists for both quinine and quinidine. Although the risk to the toddler exposed to one or two tablets seems to be small, triage to an Emergency Department is warranted after quinidine ingestion of any amount and after quinine ingestion that exceeds the age-appropriate therapeutic dose.


Subject(s)
Poison Control Centers/statistics & numerical data , Quinidine/poisoning , Quinine/poisoning , Child, Preschool , Dose-Response Relationship, Drug , Drug Overdose/mortality , Drug Overdose/physiopathology , Humans , Infant , United States
3.
Circulation ; 107(11): 1497-501, 2003 Mar 25.
Article in English | MEDLINE | ID: mdl-12654606

ABSTRACT

BACKGROUND: Previous work has suggested that platelet glycoprotein IIb/IIIa receptor blockade may confer benefit in the treatment of acute myocardial infarction. The TIGER-PA pilot trial was a single-center randomized study to evaluate the safety, feasibility, and utility of early tirofiban administration before planned primary angioplasty in patients presenting with acute myocardial infarction. METHODS AND RESULTS: A total of 100 patients presenting with acute myocardial infarction were randomized to either early administration of tirofiban in the emergency room or later administration in the catheterization laboratory. The primary outcome measures were initial TIMI grade flow, corrected TIMI frame counts, and TIMI grade myocardial perfusion ("blush"). Thirty-day major adverse cardiac events were also assessed. Angiographic outcomes demonstrate a significant improvement in initial TIMI grade flow, corrected TIMI frame counts, and TIMI grade myocardial perfusion when patients are given tirofiban in the emergency room before primary angioplasty. The rate of 30-day major adverse cardiac events suggests that early administration may be beneficial. CONCLUSIONS: This pilot study suggests that early administration of tirofiban improves angiographic outcomes and is safe and feasible in patients undergoing primary angioplasty for acute myocardial infarction.


Subject(s)
Angioplasty, Balloon, Coronary , Myocardial Infarction/drug therapy , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Tyrosine/therapeutic use , Chemotherapy, Adjuvant , Coronary Angiography , Coronary Thrombosis/diagnostic imaging , Emergency Medical Services , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/therapy , Pilot Projects , Tirofiban , Treatment Outcome , Tyrosine/adverse effects , Tyrosine/analogs & derivatives
4.
J Adolesc Health ; 32(1): 89-93, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12507807

ABSTRACT

Patients with occult pituitary adenomas infrequently present with pituitary apoplexy. Precipitation of pituitary apoplexy by gonadotropin releasing hormone or gonadotropin releasing hormone agonists has been described. The pathophysiologic mechanism by which these agents induce apoplexy remains unclear. We describe a case of pituitary apoplexy in a young woman receiving leuprolide in preparation for ovum donation. Severe hyponatremia, cerebral vasospasm and infarction, and diabetes insipidus complicated this patient's prolonged hospital course. To our knowledge, pituitary apoplexy after gonadotropin releasing hormone agonist use for ovum donation has not been previously described. The use of leuprolide or other gonadotropin releasing hormone agonists for pituitary down-regulation in conjunction with ovarian stimulation can have serious consequences in women harboring unrecognized pituitary adenomas. Thorough endocrine screening should be performed prior to initiating therapy.


Subject(s)
Fertility Agents, Female/adverse effects , Leuprolide/adverse effects , Oocyte Donation , Pituitary Apoplexy/chemically induced , Adult , Female , Humans , In Vitro Techniques , Magnetic Resonance Imaging , Pituitary Apoplexy/diagnosis , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...